论文部分内容阅读
根据与抗流感药物扎那米韦 (ｚａｎａｍｉｖｉｒ,Ｒｅｌｅｎｚａ)吸入剂有关的严重副作用事件的报告 ,葛兰素威康公司已经修改了扎那米韦的标签 ,并就此改变致函给医生及有关人士。这些事件包括患有气喘和慢性阻塞性肺疾病 (ＣＯＰＤ)患者使用扎那米韦后引起支气管痉挛及呼吸作
According to the report of a serious side-event involving inhalation of the anti-flu drug zanamivir (Relenza), GSK has modified the label of zanamivir and sent a letter of change to the doctor and the person concerned . These include bronchospasm and respiration after the use of zanamivir in patients with asthma and chronic obstructive pulmonary disease (COPD)